Efficacy and safety of digoxin in acute heart failure triggered by tachyarrhythmia

J Intern Med. 2022 Dec;292(6):969-972. doi: 10.1111/joim.13565. Epub 2022 Sep 6.

Authors

Samyut Shrestha^{1

2}, Pedro Lopez-Ayala^{1

2}, Ibrahim Schaefer¹, Svetlana S Nardiello¹, Androniki Papachristou¹, Fatima Aliyeva¹, Cornelia Simmen¹, Desiree Wussler^{1

2}, Maria Belkin^{1

2}, Danielle M Gualandro^{1

2}, Christian Puelacher^{1

2}, Eleni Michou^{1

2}, Otmar Pfister¹, Roland Bingisser^{2

3}, Christian H Nickel^{2

3}, Tobias Breidthardt^{2

4}, Christian Mueller^{1

2}

Affiliations

¹ Cardiovascular Research Institute Basel (CRIB) and Department of Cardiology, University Hospital Basel, University of Basel, Basel, Switzerland.
² GREAT Network, Rome, Italy.
³ Department of Emergency Medicine, University Hospital Basel, University of Basel, Basel, Switzerland.
⁴ Department of Internal Medicine, University Hospital Basel, University of Basel, Basel, Switzerland.

No abstract available

Keywords: acute heart failure; digoxin; tachyarrhythmia.

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Digoxin* / adverse effects
Heart Failure* / complications
Heart Failure* / drug therapy
Humans
Tachycardia / chemically induced
Tachycardia / drug therapy

Substances

Digoxin